Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Guardant steps into a new arena
A test that tracks response to therapy is useful, but approval and reimbursement will be key.
Aduhelm approval amplifies amyloid assays
Biogen needs blood tests for amyloid beta to progress quickly – and several are in the pipeline.
Asco 2021 – Guardant shoots for the moon
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
